Journal article
Future Therapeutic Directions for Smac-Mimetics
Emma Morrish, Gabriela Brumatti, John Silke
Cells | MDPI | Published : 2020
DOI: 10.3390/cells9020406
Abstract
It is well accepted that the ability of cancer cells to circumvent the cell death program that untransformed cells are subject to helps promote tumor growth. Strategies designed to reinstate the cell death program in cancer cells have therefore been investigated for decades. Overexpression of members of the Inhibitor of APoptosis (IAP) protein family is one possible mechanism hindering the death of cancer cells. To promote cell death, drugs that mimic natural IAP antagonists, such as second mitochondria-derived activator of caspases (Smac/DIABLO) were developed. Smac-Mimetics (SMs) have entered clinical trials for hematological and solid cancers, unfortunately with variable and limited resul..
View full abstractGrants
Awarded by Leukemia & Lymphoma Society SCOR (Specialized Centre of Research)
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by Leukaemia Foundation Australia priority grant
Awarded by NHMRC fellowship
Awarded by Victoria Cancer Agency (VCA) mid-career fellowship
Awarded by Australian Government NHMRC IRIISS
Funding Acknowledgements
This research was funded by a Leukemia & Lymphoma Society SCOR (Specialized Centre of Research, grant #7015-18 to J.S.), the National Health and Medical Research Council (NHMRC; grants 1025594, 1046010, and 1081376), a Cancer Australia and Leukaemia Foundation Australia priority grant (PdCCRS 1162023 to G.B.), NHMRC fellowship (1107149 to J.S.) and a Victoria Cancer Agency (VCA) mid-career fellowship (MCRF 15027 to G.B.). This work was made possible through the Australian Cancer Research Foundation and Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS (9000433).